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Zinc is a trace metal with in vitro activity against rhinovirus, the major etiologic agent in acute upper
respiratory tract infections (URIs). A previous trial of zinc gluconate supported its efficacy in treating URIs,
but the effectiveness of blinding was uncertain. We conducted a prospective randomized trial of zinc gluconate
versus a taste-matched placebo of sucrose octaacetate. Lozenges containing either 23 mg of elemental zinc or
placebo were taken every 2 h. Eleven URI symptoms were rated daily on a scale of 0 (not present) to 3 (severe).
Duration of illness, reflected in the proportion of subjects remaining symptomatic on each day, was not
significantly reduced (maximum difference of 12.6% on day 7, P = 0.09; 95% confidence interval, -6 to 31%)
by either treatment. Severity of illness, assessed by using a summed severity score, was reduced incrementally
by 7 to 8% on days 5 to 7 (P = 0.02) in subjects taking zinc. Adverse effects, mostly nausea and altered taste,
were reported by 50% of subjects taking zinc. We conclude that while zinc gluconate may produce a small
reduction in overall severity of symptoms, this is not clinically significant. Given the additional high incidence
of adverse effects, zinc gluconate cannot be recommended for use in the treatment of acute URIs.
Rhinovirus is the principal causative agent in acute upper
respiratory tract infections (URIs) (6). Although alpha 2
interferon has been demonstrated to have prophylactic effi-
cacy in rhinoviral colds (7), no effective antiviral drug is
available to treat the symptomatic illness. Zinc ions have
been found to reversibly inhibit rhinovirus replication in
vitro, possibly by complexing with capsid proteins, prevent-
ing them from acting as substrates for proteases (8). In a
previous randomized clinical trial (3), zinc gluconate in a
lozenge form was reported to reduce the mean duration of
URIs by about 4 days and to significantly reduce the severity
of symptoms. The taste of zinc gluconate is quite distinctive,
however, and we were concerned that the effectiveness of
blinding in the initial trial might have been compromised. We
therefore conducted a prospective randomized double-
blinded trial of zinc gluconate in naturally acquired URI,
using a protocol identical to that in the previous study, but in
addition used a taste-matched placebo of sucrose octaace-
tate.
MATERIALS AND METHODS
Study population. Subjects were recruited from among the
students of three colleges and from one family practice
during January to May 1986. All eligible subjects had a
clinical diagnosis of acute URI. No viral cultures were
taken.
Potential subjects were excluded from the study if they
had serious acute or chronic medical conditions, seasonal
allergies, productive cough, or indication for antibiotic ther-
apy or had taken treatment for symptoms within 8 h of the
baseline evaluation. All those enrolled were over 18 years
old and gave written informed consent. Subjects were in-
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formed of the positive outcome of the initial study and were
told that the purpose of the present study was to confirm this
result.
Medication and randomization. Identical-appearing loz-
enges containing either 11.5 mg of elemental zinc or sucrose
octaacetate were used. The latter was chosen because its
taste empirically approximated that of zinc gluconate. Upon
enrollment, subjects were randomly assigned to receive
either zinc gluconate or placebo. Both subjects and investi-
gators were blinded to treatment.
An initial dose of four lozenges was used, followed by two
lozenges dissolved in the mouth every 2 h while awake. This
course was continued for 7 days or 24 h after the disappear-
ance of the last symptom. Subjects were not allowed to use
additional cold or analgesic preparations. Compliance was
assessed through daily estimates by the subjects of the
number of lozenges consumed and pill counts by the inves-
tigators.
In order to assess the efficacy of blinding, a subsample of
40 subjects were asked at the conclusion of the trial to
indicate whether they had been taking zinc or placebo. Their
responses were compared with their actual assignments by a
chi-square test of significance.
Illness surveillance and toxicity monitoring. Upon enroll-
ment and at the end of each study day, subjects rated the
severity of 11 symptoms and the overall severity of their
URI on a scale of 0 to 3 (absent to severe). The individual
symptoms assessed were sneezing, runny nose, stopped-up
nose, sore or scratchy throat, hoarseness, postnasal drip,
cough, watery eyes, headache, chilliness, and muscle aches.
Any potential adverse effects were recorded daily. All 170
subjects enrolled, including dropouts, were surveyed for
toxic effects.
Assessment of efficacy. The effect of treatment on duration
of illness was assessed by comparing the proportion of
subjects reporting symptoms on each day of the trial. The
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FIG. 1. Effect of zinc gluconate on duration of URI.
effect on severity of illness was assessed by comparing
changes from the baseline in the summed severity score
(sum of the individual ratings for each symptom) on each
day. Subjects were excluded from analysis for insufficient
dose (less than 10 lozenges on any day) or duration of
therapy and for loss to follow-up. All comparisons were
made with a two-way analysis of variance in order to be
sensitive to significant improvements occurring only early or
later in therapy. Confidence intervals were calculated for
differences in response rates (9).
RESULTS
Study population. Of 174 eligible subjects with a clinical
diagnosis of acute URI, 88 were assigned to receive placebo
and 86 were assigned to receive zinc gluconate. Thirty-five
subjects in the placebo group and 29 taking zinc were
excluded from analysis for reasons of insufficient dose or
duration of therapy. Only two in each group were lost to
follow-up. The remaining groups of 53 subjects taking pla-
cebo and 57 taking zinc did not differ with respect to age,
sex, initial severity score, number of symptoms, or duration
of symptoms.
Effect on duration and severity of illness. The duration of
illness, reflected in the proportion of subjects who continued
to have symptoms on each day of treatment, was not
affected by zinc gluconate. Response to zinc did not become
directionally superior to placebo until the sixth study day
(Fig. 1), and the maximal difference of 12.6% seen on day 7
was not statistically significant (P = 0.09; 95% confidence
interval, -6 to 31.2% difference).
The severity of illness is reflected in the sum of the
individual symptom severity scores on any day as a propor-
tion of the baseline score. Subjects taking zinc gluconate had
lower severity scores than those in the corresponding pla-
cebo group on days 4 to 7 of treatment (Fig. 2). This
difference is statistically significant (P = 0.02; 95% confi-
dence interval, 1 to 16% difference); however, the incremen-
tal improvement in severity score of 7 to 8% is small in
clinical terms.
Adjustments in analysis for dosage taken or delay in
initiation of treatment from the onset of symptoms did not
alter these findings.
Adverse effects of medication. Adverse effects of treat-
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FIG. 2. Effect of zinc gluconate on severity of URI.
ment, mostly minor, were reported by 50% of subjects taking
zinc gluconate (Table 1).
Adequacy of blinding. In a comparison of which compound
the subjects guessed they had received with the actual
assignment, 19 subjects (47%) correctly identified whether
they were on zinc gluconate or placebo, while the other 53%
were either incorrect or uncertain. Of those given zinc
gluconate, 57% identified it correctly, while 32% of subjects
given placebo incorrectly thought it was zinc. The ability to
discriminate between zinc gluconate and sucrose octaacetate
was not significant (P = 0.24).
DISCUSSION
We found that zinc gluconate, when used to treat naturally
acquired acute URIs, produced a minor reduction in the
overall severity of symptoms late in the course of therapy
and had no effect on the duration of symptoms. These
findings stand in sharp contrast to those reported in an
earlier clinical trial with a parallel design (Eby et al. [3]). In
their study, zinc gluconate was significantly more effective in
reducing the severity and duration of symptoms, beginning
on the first day of treatment.
While our study was designed to replicate the previous
trial and so used identical doses of zinc gluconate and
identical outcome measures, there were important differ-
ences which might explain the disparity in findings. The first
is the element of blinding. The Eby et al. trial used an
unflavored placebo, while zinc gluconate has a strong me-
tallic taste. That subjects were able to discern a difference is
TABLE 1. Adverse effects of treatment
% of subjects
Adverse effect
Zinc Placebo
Nausea 24 16
Altered taste 11 3
Dry mouth 15 6
Abdominal pain/dyspepsia 5 0
Headache 6 2
Dizziness 0 5
Weakness 0 4
Constipation 1 1
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suggested by the high dropout rate (30%) in the zinc group in
that study, nearly double that in the placebo group. We
formulated a placebo which empirically matched the zinc
gluconate in taste. Our success in blinding is supported by
the inability of subjects in our trial to distinguish between the
zinc and placebo and by a dropout rate attributable to
unpalatability that was equal in both the zinc and placebo
groups (and equal to that of the zinc group in the Eby et al.
study). The slight trend in this study in favor of identification
of zinc, even if significant, would have produced a bias in
favor of the zinc treatment. The positive effect on outcome
in the earlier study when blinding was not addressed is
reminiscent of the misleading early reports of the efficacy of
ascorbic acid in treatment of the common cold (1).
A second difference between the studies was the time of
year during which each study was conducted. The Eby et al.
trial accrued patients during the fall, while our study was run
during the spring. The viral agents causing the illnesses were
not confirmed in either study. It is possible that etiology in
the two populations differed markedly, but rhinovirus has
seasonal peaks in both the spring and fall (5) and is the
predominant etiologic agent in URIs in adults. In addition,
since viral cultures are not generally used in the diagnosis of
acute URI, the etiologic agents in our study sample are likely
to be similar to those in a population in which zinc would be
used based on clinical diagnosis.
While our findings do not agree with those of Eby et al.,
they do correspond with those of two subsequent studies.
Farr and associates (4) administered zinc gluconate lozenges
to subjects with experimentally induced rhinovirus infec-
tions. They were unable to demonstrate an effect of zinc on
the severity or duration of cold symptoms, the frequency or
duration of viral shedding, or viral titers. Nasal mucous
weights and number of tissues used were higher in subjects
taking zinc gluconate. Douglas et al. (2) used effervescent
zinc acetate lozenges in subjects with naturally acquired
URIs. There were no differences in effect on severity or
duration of symptoms between zinc and placebo recipients.
The mean duration of symptoms was 4.4 days longer in
subjects taking zinc acetate. Both of these studies were
limited, however, by having too few subjects to eliminate the
possibility of a type II error. Our study had nearly twice as
many subjects as the Eby et al. trial, with more than
adequate power to detect the magnitude of differences that
they reported.
We conclude that in a carefully blinded trial, zinc gluco-
nate lozenges are not superior to placebo in the treatment of
naturally acquired acute URIs.
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